Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The role of CD95 and CD95 ligand in cancer


A Corrigendum to this article was published on 07 April 2015


CD95 (Fas/APO-1) and its ligand, CD95L, have long been viewed as a death receptor/death ligand system that mediates apoptosis induction to maintain immune homeostasis. In addition, these molecules are important in the immune elimination of virus-infected cells and cancer cells. CD95L was, therefore, considered to be useful for cancer therapy. However, major side effects have precluded its systemic use. During the last 10 years, it has been recognized that CD95 and CD95L have multiple cancer-relevant nonapoptotic and tumor-promoting activities. CD95 and CD95L were discovered to be critical survival factors for cancer cells, and were found to protect and promote cancer stem cells. We now discuss five different ways in which inhibiting or eliminating CD95L, rather than augmenting, may be beneficial for cancer therapy alone or in combination with standard chemotherapy or immune therapy.


  • CD95 is a surface receptor that has the capacity to mediate apoptosis induction in cancer cells.

  • To induce apoptosis, CD95 recruits a number of proapoptotic factors including caspase-8 to form the death-inducing signaling complex when stimulated by CD95 ligand (CD95L).

  • Immune cells (i.e., cytotoxic killer and natural killer cells) use CD95L as one mechanism to kill cancer cells or virus-infected cells.

  • Most cancer cells are resistant to CD95-mediated apoptosis.

  • CD95L can not be used systemically for cancer therapy because of the side effects due to apoptosis induction in hepatocytes.

Open Questions

  • Why do most if not all cancer cells express both CD95 and CD95L?

  • Why do cancer cells acquire mutations in CD95 usually only in one allele?

  • Why are the cancer cells that are sensitive to CD95-mediated apoptosis (at least in vitro) among the most sensitive of any cells?

CD95/CD95L in the Immune System

CD95 (Fas/APO-1/TNFRSF6), a cell surface protein that belongs to the tumor necrosis factor receptor family, can mediate apoptosis when bound to its natural ligand, CD95L (CD178/TNFSF6) or stimulated with agonistic antibodies. It is ubiquitously expressed in the body, but is particularly abundant in the thymus, liver, heart, and kidney. CD95L is predominantly expressed in activated T lymphocytes and natural killer cells, and is constitutively expressed in tissues of ‘immune-privilege sites’ such as the testis and eye.1 Experiments with mutant mice have demonstrated the importance of CD95-mediated apoptosis in the maintenance of cell homeostasis and in the deletion of useless or autoreactive T cells.1, 2, 3 A mutation found in the lpr (lymphoproliferation) mouse strain causes defective expression of CD95. Lpr mice develop lymphadenopathy and suffer from a systemic lupus erythematosus-like autoimmune disease.4 A second mouse strain (gld, generalized lymphoproliferative disease) expresses a mutant form of CD95L. Gld mice have an abnormal phenotype similar to lpr mice, which includes lpr and autoimmune disease.5 Complete knockout mice lacking either CD95 or CD95L expression also show an autoimmune phenotype that is more pronounced than the one seen in lpr or gld mice.6, 7, 8 A third mutant mouse strain with an lpr-like phenotype (lprcg) was found to have a point mutation (T to A) in the center of the CD95 cytoplasmic region. This mutation generates a receptor in which the ability to transduce an apoptotic signal is blocked.9 In a related human condition, autoimmune lymphoproliferative syndrome (ALPS),10 ALPS type Ia patients carry dominant-negative mutations in CD95 and type Ib patients have mutations in CD95L, resembling mice with lprcg and gld mutations, respectively.

Canonical Signaling of CD95 in Cancer

CD95 is predominantly located at the cell surface, where it has been shown to pre-associate in homotrimers.11 Similar to all death receptors, CD95 carries a conserved stretch of 80 amino acids in its cytoplasmic tail, the death domain (DD), that is essential for apoptosis initiation.1, 12, 13 Upon binding of CD95L, the CD95 DD assembles the death-inducing signaling complex (DISC) composed of CD95, the adaptor molecule FADD (Fas-associated with a death domain), procaspase-8, procaspase-10, and the caspase-8/10 regulator c-FLIP.13 Activated caspase-8 then initiates the apoptotic program by cleaving various intracellular proteins resulting in the execution of apoptosis.14 Likely, the most established proapoptotic activity of CD95 is to mediate the apoptotic death of either virus-infected or cancer cells when engaged by a CD8+ cytotoxic lymphocyte (CTL; Figure 1). In addition to the perforin/granzyme pathway15 and some indirect mechanisms involving cytokines such as tumor necrosis factor-α (TNFα) and interferon-γ,16, 17, 18, 19, 20, 21, 22, 23 CD95/CD95L is a direct major system that both CTLs as well as CD4+ cytolytic effector T cells use to eliminate neoplastically transformed cells.24, 25, 26, 27, 28, 29 CD95 can also mediate receptor interacting protein (RIP)-1-dependent necroptosis under circumstances of caspase inhibition or knockdown of TRAF2.30, 31 However, the physiological relevance of this activity for cancer has not been established. Expression of CD95 and CD95L by cancer cells implies that they are themselves resistant to CD95-mediated apoptosis. Indeed, most cancer cells are relatively resistant to CD95-induced apoptosis even with high levels of CD95 at the surface of the cells.32 Cancer cells have multiple ways of becoming resistant to a possible apoptotic insult mediated by CD95. A common mechanism used by the cells is to regulate cell surface expression of the receptor.33, 34 The CD95 apoptotic signal can also be inhibited at the level of the DISC via increased expression of cFLIP (cellular FLICE inhibitory protein), which can inhibit the interactions of caspase-8 and -10 with the DISC,35 or via reduced expression of FADD36 or caspase-8.37, 38 Loss of apoptosis signaling through CD95 can also be the consequence of deregulation of the expression of the Bcl-2 family proteins or inhibitor of apoptosis proteins, thereby favoring tumor survival.39

Figure 1
figure 1

The canonical apoptosis-inducing function of the CD95/CD95L system in killing cancer cells. Cancer cells that are recognized by CTLs in an antigen-specific way are being attacked by direct mechanisms: release of perforin/granzyme (shown as GrB) or use of CD95L to engage CD95 on the surface of cancer cells. Alternatively, indirect mechanisms are activated that result in upregulation of cytokines such as TNFα and INFγ, which in turn cause upregulation of CD95 and MHC-I (by IFNγ) or induction of cell death through cancer-expressed TNF receptors (by TNFα). Ag, antigen; CTL, cytotoxic lymphocyte; GrB, granzyme B; IFNγ, interferon γ; MHC-I, major histocompatibility complex I; TCR, T-cell receptor; TNFα, tumor necrosis factor α

Other Activities of the Apoptosis-inducing Receptor CD95

In addition to the activities of CD95 and CD95L in mediating apoptosis induction, mostly in the contest of an immune response,1, 2, 3 it is now established that CD95 has multiple nonapoptotic activities.40, 41, 42, 43 For example, CD95 is required for efficient liver regeneration following partial hepatectomy;44, 45 CD95 activation stimulates renal tubular epithelial cell migration by a β8 integrin-dependent mechanism,46 and CD95 provides a mitogenic signal in quiescent hepatic stellate cells through activating epidermal growth factor receptor (EGFR).47 CD95 is also important for neurite outgrowth.48, 49 CD95 and CD95L have additional, cancer-relevant, activities. We have identified at least five cancer-relevant activities of CD95 that could be targeted for cancer therapy, and one (apoptosis induction through CD95) that should not be (Figure 2).

Figure 2
figure 2

Graphical summary of the role of CD95/CD95L in cancer. Together with the tumor-suppressing ability to trigger apoptosis in (apoptosis sensitive) cancer cells (1), CD95L has a range of tumor-promoting activities, some of which are indirect, such as the suppression of the immune response in the cancer micro-environment by either tumor-generated CD95L (2) or by CD95L expressed by endothelial cells (3), and some of which are direct, such as the promotion of tumor growth and invasiveness (4) or the acquisition of a CSC phenotype (5). Importantly, a low-baseline level of CD95/CD95L signaling is required for survival of cancer cells. Elimination of CD95/CD95L signaling leads to an irreversible and effective type of cell death, DICE, which predominantly affects CSCs (6). CSC, cancer stem cell, CTL; cytotoxic T lymphocyte; IL-10, interleukin 10; EMT, epithelial-to-mesenchymal transition; PGE2, prostaglandin E2; TIL, tumor-infiltrating lymphocyte; VEGF-A, vascular endothelial growth factor A. Stippled arrows indicate hypothetical interactions

Apoptosis induction through CD95

Apoptosis induction is the most well-established activity of CD95, documented by thousands of publications and summarized in numerous review articles (e.g., Nagata,1 Peter and Krammer,13 and Nagata50). In the context of cancer, it is relevant that CD95L is one of only a few molecules that immune cells use to activate apoptosis to kill cancer cells (Figure 1).51 Apoptosis induction as a cancer cell killing strategy is presumed to be accomplished by tumor-infiltrating lymphocytes expressing CD95L (Figure 2-1, apoptosis). Apoptosis induction in cancer cells through CD95 is the only scenario in which recombinant CD95L could be used for cancer therapy. However, given the fact that almost all established cancers express CD95, and the fact that most cancer cells are resistant to apoptosis induction, we would suggest that stimulating CD95 on cancer cells may not be an effective approach to killing cancer cells. In addition, stimulation of CD95 could never be used therapeutically because of major side effects such as massive apoptosis induction in the liver.52 Based on recent data, we propose that inhibiting the activity of CD95L or targeting CD95L mRNA may be more effective for cancer therapy than using CD95L to induce apoptosis in cancer cells:

The tumor strikes back

It has been demonstrated a number of times that expression of CD95L by apoptosis-resistant tumor cells enables a powerful ‘counterattack’ against antitumor immune effector cells, such as cytotoxic killer cells, many of which are themselves sensitive to CD95L-mediated apoptosis53, 54, 55 (Figure 2-2, tumor counterattack). However, while there is some evidence for the occurrence of this counterattack, its existence remains controversial.56 The reported increased concentration of soluble CD95L (sCD95L) in the serum of many cancer patients was often interpreted in the context of the CD95L counterattack theory (Table 1). Upregulation of CD95L in patient sera would suggest a possible immunosuppressive role for this molecule. However, the generalized immune suppression that would be expected from this situation could not be confirmed in cancer patients; thus, it may be that the increase in CD95L expression in tumor tissues has a more direct role in tumor progression.

Table 1 Tumor-promoting activities of CD95 and CD95L in clinical studies

The tumor endothelium expresses CD95L

Recently, the tumor strikes back concept was rediscovered in a different form. CD95L is expressed on the tumor endothelium in mice and humans57, 58 (Figure 2-3, endothelial cell barrier). CD95L was reported to be expressed by tumor epithelium of various human solid cancers but not by normal endothelial cells.59 Tumor cells were found to cause upregulation of membrane-bound (m)CD95L on endothelial cells through the action of interleukin 10, prostaglandin E2, and vascular endothelial growth factor A. Interestingly, mCD95L only induced apoptosis of effector killer T cells but not of regulatory T cells, which were found to be protected by expression of a number of antiapoptotic proteins including cFLIP, Bcl-2, and Bcl-xL. This finding was supported by a syngeneic in vivo mouse model of ovarian cancer, in which it was demonstrated that expression of CD95L on endothelial cells causes reduced CD8 T-cell infiltration into the tumor. Finally, it was shown that mice treated with a neutralizing anti-CD95L antibody show increased infiltration of adoptively transferred tumor vaccine-primed CD8 T cells.59 These data suggest that inhibiting endothelial CD95L expression could be a new therapeutic strategy to enhance the potency of adoptive transfer of antitumor T cells.

The tumor-promoting activities of CD95

Although the concept of inducing apoptosis in cancer cells using death ligands such as CD95L was intriguing, it was unlikely that the only function of CD95 was to induce apoptosis. As early as 1993,60 it was recognized that CD95 also induces proliferation in various cell types such as T cells, liver cells, and neurons.45, 48, 49, 61, 62, 63 In 2004, we reported that stimulation of CD95 on 22 apoptosis-resistant cancer cell lines increases their motility and invasiveness in vitro.64 In a study with cells from ALPS patients, as well as cellular and mouse model systems, we demonstrated that nonapoptotic signaling through CD95 involved activation of NF-κB and the three MAP kinases, Erk1/2, JNK1/2, and p38.64, 65, 66, 67 In addition, we demonstrated in various cancer cell lines that CD95-mediated invasiveness requires activation of NF-κB and ERK, and involves active caspase-8 and urokinase plasminogen activator.64 It is now widely accepted that once cancer cells acquire resistance to CD95-mediated apoptosis, further stimulation of CD95 is tumorigenic (Figure 2-4, invasiveness and growth).64, 68, 69, 70, 71, 72, 73, 74, 75 CD95L is expressed in two flavors, a membrane-bound form and a soluble form that is generated through cleavage of mCD95L by metalloproteinases.76, 77 mCD95L in vivo is essential for apoptosis induction, whereas sCD95L has nonapoptotic activities and may be the predominant tumor-promoting activity in vivo.78 The concept that CD95 can be a tumor promoter has now gained wide acceptance, supported by a number of reports describing marked activities of CD95 in tumor growth and spread (Table 2).

Table 2 Tumor-promoting activities of CD95 and CD95L in vitro and in mouse models

CD95 is coupled to multiple potentially tumorigenic signaling pathways. CD95 was identified in a small hairpin RNA (shRNA) screen as a modifier that renders human lung adenocarcinomas resistant to EGFR tyrosine kinase inhibitors through activation of NF-κB.79 Others have demonstrated that CD95 mediates invasion via the Src/PI3K/GSK3β/MMP (matrix metalloproteinase) pathway;74, 80 however, the transactivation of tyrosine kinases by CD95 is incompletely understood. In colon cancer, it was shown that activated CD95 promotes the formation of cell protrusions through a new signaling pathway involving platelet-derived growth factor receptor-beta mediated phospholipase C-γ activation and phosphatidylinositol (4,5)-bisphosphate hydrolysis.81 The subsequent release of cofilin from the plasma membrane and the continued suppression of LIMK1 by Kras/RAF1 together allow robust activation of the cofilin pathway. Cofilin activation was shown to be required for CD95-stimulated formation of membrane protrusions and increased tumor cell invasion. Recently, metalloproteinase-cleaved CD95L was reported to trigger a motility-inducing signaling complex formation in triple-negative breast cancer cells.82 Most recently, it was shown that CD95-mediated activation of Sck/Shc2 is indispensable for cell cycle progression of metastatic pancreatic ductal adenocarcinoma (PDAC).83 These data suggest that CD95 is connected to a myriad of prosurvival and migratory signaling pathways.

We recently tested the relevance of these nonapoptotic functions of CD95 and CD95L for cancer cells. We knocked down either CD95 or CD95L in numerous cancer cell lines using multiple small interfering RNA (siRNAs) and shRNAs. This resulted in a profound reduction in growth of the cancer cells.44 In addition, we generated tissue-specific knockout mice lacking CD95 expression in the liver or on the surface epithelial cells of the ovaries. Using appropriate tumor mouse models, we found a severe reduction in liver cancer in mice lacking CD95 in hepatocytes (diethylnitrosamine injection model), and mice lacking CD95 in the ovaries barely developed cancer at all (using the KrasD12G/pten−/− endometrioid ovarian cancer model84). Finally, it was shown that mice that only express soluble but not mCD95L suffer from large histiocytic sarcomas in the liver,78 likely owing to a lack of apoptosis induction and a tumorigenic activity of CD95L.

A number of studies reported CD95 as a positive prognostic marker for cancer.85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 This is likely owing to the fact that CD95 is often downregulated during tumor progression because cancer cells need to lower the risk of undergoing apoptosis while benefiting from CD95’s tumorigenic activities. Occasionally, CD95L was also described as a positive prognostic marker for cancer.86, 100, 101 However, the vast majority of reports have shown that disease progression is associated with progressively increased expression of CD95L and sometimes also CD95, and expression of both CD95 and especially of CD95L in most cases act as negative prognostic markers for many cancers (Table 1). In summary, most studies suggest that CD95 and/or CD95L expression promotes tumor growth and favors the establishment of tumor metastases.

Maintenance of CSCs by CD95 and CD95L

The cancer stem cell (CSC) model is an attractive hypothesis that translates properties of normal stem cells into the cancer field, and explains some of the most lethal features of cancers. The CSC model proposes that the cells within a tumor are hierarchically organized, and it predicts the existence of a subpopulation of cells with high tumorigenicity that are able to both self–renew and to generate differentiated cells (non-CSCs).102, 103 One of the most malignant features of cancer is the appearance of relapses, sometimes years after radiotherapy or chemotherapeutical intervention, and this has been related to the occurrence of cells with the CSC phenotype.104 Therefore, elucidating the mechanisms of CSC maintenance is important for understanding tumor cell persistence and relapse, and may enable specific targeting of CSCs, a promising therapeutic strategy to stably eradicate cancer.105, 106

CD95 and CD95 signaling have been connected to normal stem cells.45, 107 CD95 was, in fact, previously identified as a candidate stem cell marker (along with well-established stem cell markers such as Lin28, Oct4, Nanog, and Sox2, among others) in a serial analysis of gene expression profiling of human embryonic stem cells.108 Functional evidence of a prosurvival function of CD95 and CD95L signaling in normal stem cells came from experiments that showed that the stimulation of CD95 signaling in neuronal stem cells did not cause death, but rather increased the survival of neuronal stem cells via a Src/PI3K/AKT/mTOR signaling pathway, while, conversely, deletion of CD95 resulted in reduced neurogenesis.107 Because normal stem cells are often the origin of CSCs, these data were suggestive that CD95 may also have a nonapoptotic function in CSCs.

In the context of cancer, CD95 expression and CD95 signaling have been connected with the differentiation of cells. We reported this based on an analysis of the NCI-60 panel of cancer cells, which could be divided in two super-clusters with distinct differentiation stages that responded differently to CD95 stimulation.109 Interestingly, expression of CD95 inversely correlated with expression of the stem cell-inhibiting members of the let-7 family of micro RNAs (miRNAs), and stimulation of CD95 caused a reduction in let-7 expression.110 Moreover, and related to this, CD95 has been shown to be capable of inducing the epithelial-to-mesenchymal transition (EMT) differentiation program in gastrointestinal cancer111, 112 (Figure 2-5, EMT and CSC maintenance). In these studies, the authors demonstrated that CD95 signaling inactivates GSK3β by ERK/mitogen-activated protein kinase signaling resulting in increased nuclear import and interaction between AP-1 and NFAT4. This increases their transcriptional activity leading to nuclear accumulation of Snail and β-catenin and miR-23a expression, and subsequently, downregulation of E-cadherin and upregulation of MMP9 and vimentin in vivo and in vitro.111, 113 EMT has been previously connected with the generation of cells with the properties of CSCs.114

We recently demonstrated that CD95 is required for the survival of CSCs and allows new CSCs to emerge115 (Figure 2-5, EMT and CSC maintenance). Stimulation of CD95 on multiple tumor cells induced a conversion from non-CSCs to CSCs. This reprogramming activity of CD95 was independent of its apoptosis-inducing function, as it was not blocked by the pan-caspase inhibitor zVAD-fmk; rather, it represents a mechanism of retro-differentiation. Strikingly, CSCs from highly apoptosis-sensitive HeyA8 ovarian cancer cells enriched in tumor spheres were found to be almost completely resistant to CD95-mediated apoptosis. For breast cancer, we could connect this novel function of CD95/CD95L to the activity of miR-200, a miRNA previously linked to both EMT and CSCs.114, 116, 117 miR-200c expression increased the sensitivity of cancer cells to CD95-mediated apoptosis.118 Stimulation of CD95 not only increased the number of cancer cells with stem cell traits but also prevented differentiation of CSCs, suggesting that CD95 expression on cancer cells maintains the CSC pool.115 A connection between CD95 and CSCs was recently also reported for PDAC.83 CD95 expression strongly correlated with stemness and EMT markers and blocking CD95L reduced tumor growth and metastasis in vivo.

Death induced by CD95R/L elimination

Following up on our finding that CD95 contributes to the proliferation of cancer cells,44 we recently reported that the elimination of either CD95 or CD95L kills cancer cells (in vitro and in vivo) in a process we termed DICE (death induced by CD95 or CD95L elimination)119 (Figure 2-6, DICE). This activity of CD95 as a survival factor seems to be mostly relevant to cancer cells, as none of the normal tissues during embryonic development in either CD95 or CD95L knockout mice showed a growth defect or signs of cell death.6, 7, 8 Consistently, we found increased sensitivity to DICE in ovarian surface epithelial cells after they were immortalized by expression of hTERT.119

We found that all cancer cells tested (~40 lines tested to date) substantially die by DICE when either CD95 or CD95L is knocked down. We used 15 different non-overlapping si/shRNAs against either of the two genes, and all induce DICE. We generated Tet-inducible vectors (pTIP) to express the shRNAs. They kill all cancer cells when doxycycline is added. In two ovarian cancer mouse models and one mouse model of chemically induced liver cancer, tumor formation was severely reduced in the absence of CD95.44, 119 In fact, a reanalysis of the tumor samples revealed that not a single cancer cell could be detected in any of the models that had deleted both alleles of CD95.119 We reported that DICE has the following properties:119

  1. 1

    DICE represents a necrotic form of mitotic catastrophe with signs of apoptosis,119 autophagy, and senescence (unpublished data).

  2. 2

    DICE is characterized by cell swelling and production of reactive oxygen species followed by DNA damage and activation of caspase-2, resulting in mitochondrial outer membrane permeabilization. Cells eventually die by a RIP1/mixed lineage-like kinase-independent mechanism. Although multiple cell death pathways are activated, RIPK-dependent necroptosis does not seem to be critical, suggesting that DICE induction may not cause inflammation.

  3. 3

    DICE could not be inhibited by any of 1200 tested drugs or by knockdown of any single gene in a genome-wide shRNA screen,119 suggesting that it is a robust cell death mechanism that is difficult to block.

We recently postulated that DICE is a fail-safe mechanism, a dead man’s switch, that prevents the survival of cancer cells that are devoid of CD95, and, hence, would not be eliminated by the immune system through CD95L/CD95-mediated apoptosis.120 Thus, DICE is a naturally occurring antitumor defense mechanism. The observation that in tumor cells both alleles of CD95 are rarely if ever mutated or deleted (reviewed in Peter et al.41) is consistent with this interpretation. Our recent data show that all cancer cells autonomously produce a small amount of CD95L, suggesting that the loss of either CD95 or CD95L induces DICE, which is consistent with our observation that cancer cells never delete both alleles of CD95.119

Our study of CSCs revealed a crucial role for CD95 signaling in regulating cancer differentiation, and indicated that the two death mechanisms, DICE and canonical CD95-mediated apoptosis, have opposing roles in eliminating CSCs and non-CSCs. Conversion of non-CSCs to CSCs resulted in a loss of sensitivity to CD95-mediated apoptosis and a concomitant increase in the sensitivity of the cells to DICE.115 In fact, we found that DICE preferentially targets CSCs.115 When DICE was induced in multiple cancer cell lines or primary breast cancer cells, they became depleted of CSCs. Cells lost typical CSC surface markers, formed spheres less efficiently, and lost expression of endogenous CSC markers while becoming enriched in the stem cell-controlling miRNA miR-200c.

Targeting CD95L to Kill Cancer Cells

The data summarized above suggest that CD95 and CD95L act as oncogenes once cancer cells have become resistant to the apoptosis-inducing activity of CD95. The data further seem to suggest that the reason that cancer cells die after removal of either CD95 or CD95L is that they are addicted to their oncogenic activities. However, for the following reasons, we would argue that DICE is not the result of a broken oncogene addiction: (1) CD95 and CD95L intrinsically have tumor-suppressive activities in the context of the immune system (see above). (2) Elimination of CD95 or CD95L can kill any cancer cell we have tested, not just cells that overexpress CD95 or CD95L. In fact, CD95L expression in most cancer cells is barely detectable, yet elimination of CD95L induces DICE more effectively in cells that express less CD95L, perhaps because CD95L becomes rate limiting more easily. CD95 and CD95L may be the first identified tumor-suppressive genes that are so important that their loss (which could occur as neoplastically transformed cells continue to acquire mutations) triggers a fail-safe program to kill such cells. An interesting aspect of this model is that, by definition, the DICE mechanism has not been triggered in any cancer cell found in a cancer patient, the implication being that cancer cells do not become resistant to DICE, but they become resistant to apoptosis and may evade DICE by retaining expression of CD95 and CD95L.

Because neither CD95 nor CD95L knockout mice are known to exhibit any defects in the proliferation of any tissue and exhibit no defects in stem cell compartments,6, 7, 8 it is possible that CD95 or CD95L could be safely targeted for therapeutic purposes. Targeting CD95L systemically would block all the tumorigenic activities summarized in Figure 2.

Inducing DICE in Combination with Standard Chemotherapy

Although induction of DICE alone may be effective in killing cancer cells, the combination of induction of DICE with existing therapies and concepts may be beneficial in improving outcomes of cancer therapy. During our analysis of the role of CD95 in CSCs, we identified a strong synergy between DICE and CD95-mediated apoptosis in eradicating cancer.115 The synergy is a direct consequence of the differential sensitivities of CSCs and non-CSCs to the two death mechanisms. Thus, a therapy that combined the two death mechanisms could be beneficial to cancer treatment by targeting two differentiation stages of cancer development. It has been reported multiple times that many forms of chemotherapy act by inducing, at least in part, apoptosis in cancer cells, sometimes through upregulation of CD95L.121, 122 It is also established that cancer patients who become refractory to therapy have an increased CSC population,123, 124 which we recently showed to be more sensitive to DICE than non-CSCs. Thus, a combination of low-dose chemotherapy coupled with targeting CD95 may be beneficial as it should target both non-CSCs and CSCs. Targeting of CD95L could also be a beneficial addition to chemotherapy because chemotherapy-induced upregulation of CD95L has been suggested to not only drive cancer cells into apoptosis but to promote growth of drug resistant tumor cells.125

Inducing DICE in Combination with Inhibition of Immune Checkpoint Receptors

An effective mechanism to treat certain cancers involves the mobilization of the immune system. Cancer cells have found ways to suppress the antitumor response mounted by the immune system, but recent successes of therapies that are aimed toward de-repressing the tumor-imposed block on the immune system are evidence of the power of these mechanisms. Anti-PDL1 and anti-PD-1 clinical trials have shown promising effects in melanoma, renal, colorectal, and non-small cell lung cancer patients, and, for the first time ever in the development of immune therapy, a sizeable fraction of patients were observed who had a durable response that increased their life span.126, 127, 128, 129 Based on these early data, one can predict that success in cancer therapy will come from harnessing natural mechanisms that control cancer in general (e.g., an antitumor immune response) rather than from cancer-specific strategies. Empowering the immune system by targeting immune check point signaling and simultaneously attacking the cancer cells by inducing DICE may represent a viable combination of therapies both of which activate preexisting antitumor mechanisms.

Conclusions and Perspectives

Using CD95L for cancer therapy was never a viable option to treat cancer because of its devastating effects on the liver. Accumulating evidence now suggests that cancer cells can never lose CD95 or CD95L and if they do, they die. This provides an opportunity to use targeting either CD95 or CD95L to treat cancer. However, there are many open questions that need to be addressed first. Although excess of CD95L secreted by tumor cells may drive EMT and stemness and render tumor cells more motile and invasive, it is not clear whether targeting this secreted protein will be enough to block the tumor-promoting activities of CD95 and CD95L. In our hands, blocking the activity of extracellular CD95L has had no effect on cell viability.119 In addition, recent data suggest that both CD95L and CD95 are located in intracellular stores,119 hence they may exert their activity to protect cancer cells from DICE from within the cell. It may therefore be necessary to target the intracellular proteins or the mRNAs of CD95 and CD95L. This will require development of more efficient ways to deliver siRNAs to cells or the development of new technologies to eliminate genes from cells all together (i.e., using the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system).



autoimmune lymphoproliferative syndrome


cytotoxic lymphocyte




CD95 ligand


cancer stem cell


death domain


death induced by CD95R/L elimination


death-inducing signaling complex


epidermal growth factor receptor


epithelial-to-mesenchymal transition


Fas-associated with a death domain


cellular FLICE inhibitory protein




generalized lymphoproliferative disease


membrane-bound CD95L


matrix metalloproteinase


pancreatic ductal adenocarcinoma


phosphoinositide-3 kinase


receptor interacting protein


soluble CD95L


small hairpin RNA


small interfering RNA


tumor necrosis factor


carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone


  1. 1

    Nagata S . Apoptosis by death factor. Cell 1997; 88: 355–365.

    CAS  Article  Google Scholar 

  2. 2

    Krammer PH . CD95's deadly mission in the immune system. Nature 2000; 407: 789–795.

    CAS  Article  Google Scholar 

  3. 3

    Peter ME, Barnhart BC, Algeciras-Schimnich A . The Cytokine Handbook: CD95L/FasL and its receptor CD95 (APO-1/Fas). Cytokine Handb 2003; 2: 885–911.

    Article  CAS  Google Scholar 

  4. 4

    Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S . Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–317.

    CAS  Article  Google Scholar 

  5. 5

    Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969–976.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. 6

    Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995; 11: 294–300.

    Article  CAS  PubMed  Google Scholar 

  7. 7

    Karray S, Kress C, Cuvellier S, Hue-Beauvais C, Damotte D, Babinet C et al. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J Immunol 2004; 172: 2118–2125.

    Article  CAS  Google Scholar 

  8. 8

    Senju S, Negishi I, Motoyama N, Wang F, Nakayama K, Lucas PJ et al. Functional significance of the Fas molecule in naive lymphocytes. Int Immunol 1996; 8: 423–431.

    Article  CAS  PubMed  Google Scholar 

  9. 9

    Kimura M, Matsuzawa A . Autoimmunity in mice bearing lprcg: a novel mutant gene. Int Rev Immunol 1994; 11: 193–210.

    Article  CAS  PubMed  Google Scholar 

  10. 10

    Bidere N, Su HC, Lenardo MJ . Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 2006; 24: 321–352.

    Article  CAS  Google Scholar 

  11. 11

    Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288: 2354–2357.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. 12

    Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME . Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 2002; 22: 207–220.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. 13

    Peter ME, Krammer PH . The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. 14

    Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997; 16: 2794–2804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. 15

    Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. 16

    Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J . Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183: 657–661.

    Article  CAS  PubMed  Google Scholar 

  17. 17

    Winter H, Hu HM, Urba WJ, Fox BA . Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J Immunol 1999; 163: 4462–4472.

    CAS  PubMed  Google Scholar 

  18. 18

    Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63: 4095–4100.

    CAS  PubMed  Google Scholar 

  19. 19

    Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R, Reimann J . T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol 1998; 161: 897–908.

    CAS  PubMed  Google Scholar 

  20. 20

    Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW et al. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001; 108: 51–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. 21

    Kowalczyk DW, Wlazlo AP, Giles-Davis W, Kammer AR, Mukhopadhyay S, Ertl HC . Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack. Cancer Gene Ther 2003; 10: 870–878.

    Article  CAS  PubMed  Google Scholar 

  22. 22

    Barth Jr RJ, Mule JJ, Spiess PJ, Rosenberg SA . Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173: 647–658.

    Article  CAS  PubMed  Google Scholar 

  23. 23

    Prevost-Blondel A, Roth E, Rosenthal FM, Pircher H . Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 2000; 164: 3645–3651.

    Article  CAS  PubMed  Google Scholar 

  24. 24

    Lowin B, Hahne M, Mattmann C, Tschopp J . Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650–652.

    Article  CAS  Google Scholar 

  25. 25

    Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528–530.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. 26

    Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H et al. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1994; 1: 357–364.

    Article  CAS  PubMed  Google Scholar 

  27. 27

    Rouvier E, Luciani MF, Golstein P . Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993; 177: 195–200.

    Article  CAS  PubMed  Google Scholar 

  28. 28

    Stalder T, Hahn S, Erb P . Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994; 152: 1127–1133.

    CAS  PubMed  Google Scholar 

  29. 29

    Ju ST, Cui H, Panka DJ, Ettinger R, Marshak-Rothstein A . Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 1994; 91: 4185–4189.

    Article  CAS  PubMed  Google Scholar 

  30. 30

    Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489–495.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. 31

    Karl I, Jossberger-Werner M, Schmidt N, Horn S, Goebeler M, Leverkus M et al. TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis. Cell Death Dis 2014; 5: e1444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. 32

    Algeciras-Schimnich A, Pietras EM, Barnhart BC, Legembre P, Vijayan S, Holbeck SL et al. Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci USA 2003; 100: 11445–11450.

    Article  CAS  Google Scholar 

  33. 33

    Ivanov VN, Lopez Bergami P, Maulit G, Sato TA, Sassoon D, Ronai Z . FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 2003; 23: 3623–3635.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. 34

    Ivanov VN, Ronai Z, Hei TK . Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis. J Biol Chem 2006; 281: 1840–1852.

    Article  CAS  Google Scholar 

  35. 35

    Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–195.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. 36

    Tourneur L, Mistou S, Michiels FM, Devauchelle V, Renia L, Feunteun J et al. Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene 2003; 22: 2795–2804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. 37

    Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM . Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001; 20: 5865–5877.

    Article  CAS  Google Scholar 

  38. 38

    Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529–535.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. 39

    Igney FH, Krammer PH . Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277–288.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. 40

    Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK et al. The CD95 receptor: apoptosis revisited. Cell 2007; 129: 447–450.

    Article  CAS  Google Scholar 

  41. 41

    Peter ME, Legembre P, Barnhart BC . Does CD95 have tumor promoting activities? Biochim Biophys Acta 2005; 1755: 25–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42

    Martin-Villalba A, Llorens-Bobadilla E, Wollny D . CD95 in cancer: tool or target? Trends Mol Med 2013; 19: 329–335.

    Article  CAS  Google Scholar 

  43. 43

    Wajant H, Pfizenmaier K, Scheurich P . Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003; 14: 53–66.

    Article  CAS  Google Scholar 

  44. 44

    Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C et al. CD95 promotes tumour growth. Nature 2010; 465: 492–496.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. 45

    Desbarats J, Newell MK . Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6: 920–923.

    Article  CAS  Google Scholar 

  46. 46

    Jarad G, Wang B, Khan S, DeVore J, Miao H, Wu K et al. Fas activation induces renal tubular epithelial cell beta 8 integrin expression and function in the absence of apoptosis. J Biol Chem 2002; 277: 47826–47833.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. 47

    Reinehr R, Sommerfeld A, Haussinger D . CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells. Gastroenterol 2008; 134: 1494–1506.

    Article  CAS  Google Scholar 

  48. 48

    Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, Newell MK . Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003; 5: 118–125.

    Article  CAS  Google Scholar 

  49. 49

    Zuliani C, Kleber S, Klussmann S, Wenger T, Kenzelmann M, Schreglmann N et al. Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ 2006; 13: 31–40.

    Article  CAS  Google Scholar 

  50. 50

    Nagata S . Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33: 29–55.

    Article  CAS  Google Scholar 

  51. 51

    Strasser A, Jost PJ, Nagata S . The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30: 180–192.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. 52

    Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806–809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. 53

    Igney FH, Behrens CK, Krammer PH . Tumor counterattack—concept and reality. Eur J Immunol 2000; 30: 725–731.

    Article  CAS  Google Scholar 

  54. 54

    Chappell DB, Restifo NP . T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother 1998; 47: 65–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. 55

    O'Connell J, O'Sullivan GC, Collins JK, Shanahan F . The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075–1082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. 56

    Igney FH, Krammer PH . Tumor counterattack: fact or fiction? Cancer Immunol Immunother 2005; 54: 1127–1136.

    Article  PubMed  PubMed Central  Google Scholar 

  57. 57

    Yu JS, Lee PK, Ehtesham M, Samoto K, Black KL, Wheeler CJ . Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium. J Neurooncol 2003; 64: 55–61.

    PubMed  PubMed Central  Google Scholar 

  58. 58

    Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 2008; 14: 324–334.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. 59

    Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20: 607–615.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. 60

    Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993; 178: 2231–2235.

    Article  CAS  Google Scholar 

  61. 61

    Kennedy NJ, Kataoka T, Tschopp J, Budd RC . Caspase activation is required for T cell proliferation. J Exp Med 1999; 190: 1891–1896.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. 62

    Alam A, Cohen LY, Aouad S, Sekaly RP . Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J Exp Med 1999; 190: 1879–1890.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. 63

    Ichikawa K, Yoshida-Kato H, Ohtsuki M, Ohsumi J, Yamaguchi J, Takahashi S et al. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000; 12: 555–562.

    Article  CAS  Google Scholar 

  64. 64

    Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME . CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004; 23: 3175–3185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. 65

    Legembre P, Barnhart BC, Zheng L, Vijayan S, Straus SE, Puck J et al. Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep 2004; 5: 1084–1089.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. 66

    Legembre P, Barnhart BC, Peter ME . The Relevance of NF-kappaB for CD95 Signaling in Tumor Cells. Cell Cycle 2004; 3: 1235–1239.

    Article  CAS  Google Scholar 

  67. 67

    Legembre P, Schickel R, Barnhart BC, Peter ME . Identification of SNF1/AMP Kinase-related Kinase as an NF-{kappa}B-regulated Anti-apoptotic Kinase Involved in CD95-induced Motility and Invasiveness. J Biol Chem 2004; 279: 46742–46747.

    Article  CAS  Google Scholar 

  68. 68

    Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH . Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis 2003; 8: 151–160.

    Article  CAS  Google Scholar 

  69. 69

    Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X . Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009; 182: 3801–3808.

    Article  CAS  Google Scholar 

  70. 70

    Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterol 2010; 138: 2357–2367.

    Article  CAS  Google Scholar 

  71. 71

    Park SM, Chen L, Zhang M, Ashton-Rickardt P, Turner JR, Peter ME . CD95 is cytoprotective for intestinal epithelial cells in colitis. Inflamm Bowel Dis 2010; 16: 1063–1070.

    Article  PubMed  Google Scholar 

  72. 72

    Yuan K, Jing G, Chen J, Liu H, Zhang K, Li Y et al. Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK). J Biol Chem 2011; 286: 24776–24784.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. 73

    Trauzold A, Roder C, Sipos B, Karsten K, Arlt A, Jiang P et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J 2005; 19: 620–622.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. 74

    Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O et al. Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma. Cancer Cell 2008; 13: 235–248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. 75

    Nijkamp MW, Hoogwater FJ, Steller EJ, Westendorp BF, van der Meulen MW, Rinkes IH et al. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. J Hepatol 2010; 53: 1069–1077.

    Article  CAS  Google Scholar 

  76. 76

    Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205–1213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. 77

    Tanaka M, Itai T, Adachi M, Nagata S . Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31–36.

    Article  CAS  Google Scholar 

  78. 78

    La OR, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009; 461: 659–663.

    Article  CAS  Google Scholar 

  79. 79

    Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011; 471: 523–526.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. 80

    Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C et al. The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol 2011; 9: e1001090.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. 81

    Steller EJ, Ritsma L, Raats DA, Hoogwater FJ, Emmink BL, Govaert KM et al. The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion. EMBO Rep 2011; 12: 931–937.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. 82

    Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F et al. CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res 2013; 73: 6711–6721.

    Article  CAS  Google Scholar 

  83. 83

    Teodorczyk M, Kleber S, Wollny D, Sefrin JP, Aykut B, Mateos A et al. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell Death Differ 2015 e-pub ahead of print 23 January 2015; doi: 10.1038/cdd.2014.217.

  84. 84

    Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T . Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11: 63–70.

    Article  CAS  PubMed  Google Scholar 

  85. 85

    Chan KW, Lee PY, Lam AK, Law S, Wong J, Srivastava G . Clinical relevance of Fas expression in oesophageal squamous cell carcinoma. J Clin Pathol 2006; 59: 101–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. 86

    Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T et al. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J Haematol 2006; 76: 465–472.

    Article  CAS  PubMed  Google Scholar 

  87. 87

    Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, Maruyama R et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005; 93: 544–551.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. 88

    Eser B, Sari I, Canoz O, Altuntas F, Cakmak E, Ozturk A et al. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma. Am J Hematol 2006; 81: 307–314.

    Article  PubMed  Google Scholar 

  89. 89

    Chatzitolios A, Venizelos I, Tripsiannis G, Anastassopoulos G, Papadopoulos N . Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma. Ann Hematol 2010; 89: 889–896.

    Article  PubMed  Google Scholar 

  90. 90

    de Carvalho-Neto PB, dos Santos M, de Carvalho MB, Mercante AM, dos Santos VP, Severino P et al. FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity. PLoS One 2013; 8: e69024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. 91

    Strater J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T et al. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005; 54: 661–665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. 92

    Asensio C, Zapata A, Garcia-Ahijado J, Gil B, Salvadores P, Schneider J . Fas expression is associated with a better prognosis in laryngeal squamous cell carcinoma. Anticancer Res 2007; 27: 4083–4086.

    PubMed  Google Scholar 

  93. 93

    Koomagi R, Volm M . Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 1999; 84: 239–243.

    Article  CAS  PubMed  Google Scholar 

  94. 94

    Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H et al. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 1999; 5: 2464–2469.

    CAS  PubMed  Google Scholar 

  95. 95

    Baryshnikov A, Polosukhina ER, Tupitsin NN, Gavrikova NV, Andreeva L, Zabotina TN et al. CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients. Adv Exp Med Biol 1999; 457: 251–258.

    Article  CAS  PubMed  Google Scholar 

  96. 96

    Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T et al. Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 1999; 35: 1462–1465.

    Article  CAS  PubMed  Google Scholar 

  97. 97

    Kase S, Osaki M, Adachi H, Kaibara N, Ito H . Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol 2002; 20: 291–297.

    CAS  PubMed  Google Scholar 

  98. 98

    Volm M, Koomagi R, Mattern J, Efferth T . Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin Cancer Res 2002; 8: 1843–1848.

    CAS  PubMed  Google Scholar 

  99. 99

    Bernstorff WV, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS et al. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer 2002; 94: 2552–2560.

    Article  PubMed  Google Scholar 

  100. 100

    Fokkema E, Timens W, de Vries EG, de Jong S, Fidler V, Meijer C et al. Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. Lung Cancer 2006; 52: 241–247.

    Article  PubMed  Google Scholar 

  101. 101

    Fathi M, Amirghofran Z, Shahriari M . Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Onc 2012; 29: 2046–2052.

    Article  CAS  Google Scholar 

  102. 102

    Charafe-Jauffret E, Ginestier C, Birnbaum D . Breast cancer stem cells: tools and models to rely on. BMC Cancer 2009; 9: 202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. 103

    Reya T, Morrison SJ, Clarke MF, Weissman IL . Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–111.

    Article  CAS  Google Scholar 

  104. 104

    Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820–13825.

    Article  PubMed  Google Scholar 

  105. 105

    Frank NY, Schatton T, Frank MH . The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120: 41–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. 106

    Gupta PB, Chaffer CL, Weinberg RA . Cancer stem cells: mirage or reality? Nat Med 2009; 15: 1010–1012.

    Article  CAS  PubMed  Google Scholar 

  107. 107

    Corsini NS, Sancho-Martinez I, Laudenklos S, Glagow D, Kumar S, Letellier E et al. The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 2009; 5: 178–190.

    Article  CAS  Google Scholar 

  108. 108

    Richards M, Tan SP, Tan JH, Chan WK, Bongso A . The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells 2004; 22: 51–64.

    Article  CAS  PubMed  Google Scholar 

  109. 109

    Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007; 104: 11400–11405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. 110

    Hau A, Ceppi P, Peter ME . CD95 Is Part of a let-7/p53/miR-34 Regulatory Network. PLoS One 2012; 7: e49636.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. 111

    Zheng H, Li W, Wang Y, Xie T, Cai Y, Wang Z et al. miR-23a inhibits E-cadherin expression and is regulated by AP-1 and NFAT4 complex during Fas-induced EMT in gastrointestinal cancer. Carcinogenesis 2014; 35: 173–183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. 112

    Zheng HX, Cai YD, Wang YD, Cui XB, Xie TT, Li WJ et al. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene 2013; 32: 1183–1192.

    Article  CAS  Google Scholar 

  113. 113

    Zheng H, Li W, Wang Y, Liu Z, Cai Y, Xie T et al. Glycogen synthase kinase-3 beta regulates Snail and beta-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. Eur J Cancer 2013; 49: 2734–2746.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. 114

    Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. 115

    Ceppi P, Hadji A, Kohlhapp F, Pattanayak A, Hau A, Xia L et al. CD95 and CD95L promote and protect cancer stem cells. Nat Commun 2014; 5: 5238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. 116

    Park SM, Gaur AB, Lengyel E, Peter ME . The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors, ZEB1 and ZEB2. Genes Dev 2008; 22: 894–907.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. 117

    Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592–603.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. 118

    Schickel R, Park SM, Murmann AE, Peter ME . mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010; 38: 908–915.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. 119

    Hadji A, Ceppi P, Murmann AE, Brockway S, Pattanayak A, Bhinder B et al. Death induced by CD95 or CD95 ligand elimination. Cell Rep 2014; 10: 208–222.

    Article  CAS  Google Scholar 

  120. 120

    Peter ME . DICE: A novel tumor surveillance mechanism - a new therapy for cancer? Cell Cycle 2014; 13: 1373–1378.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. 121

    Friesen C, Fulda S, Debatin KM . Cytotoxic drugs and the CD95 pathway. Leukemia 1999; 13: 1854–1858.

    Article  CAS  PubMed  Google Scholar 

  122. 122

    Kaufmann SH, Earnshaw WC . Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42–49.

    Article  CAS  PubMed  Google Scholar 

  123. 123

    Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109–1123.

    Article  CAS  PubMed  Google Scholar 

  124. 124

    Visvader JE, Lindeman GJ . Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717–728.

    Article  CAS  Google Scholar 

  125. 125

    Ametller E, Garcia-Recio S, Costamagna D, Mayordomo C, Fernandez-Nogueira P, Carbo N et al. Tumor promoting effects of CD95 signaling in chemoresistant cells. Mol Cancer 2010; 9: 161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. 126

    Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455–2465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. 127

    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. 128

    Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19: 462–468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. 129

    Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134–144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. 130

    Konno R, Takano T, Sato S, Yajima A . Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 2000; 6: 3576–3580.

    CAS  PubMed  Google Scholar 

  131. 131

    Osorio LM, Aguilar-Santelises M, De Santiago A, Hachiya T, Mellstedt H, Jondal M . Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol 2001; 66: 342–346.

    Article  CAS  Google Scholar 

  132. 132

    Muschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J et al. CD95 ligand expression in dedifferentiated breast cancer. J Pathol 1999; 189: 378–386.

    Article  CAS  Google Scholar 

  133. 133

    Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T . Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 2001; 92: 287–293.

    Article  CAS  Google Scholar 

  134. 134

    Mizutani Y, Yoshida O, Ukimura O, Kawauchi A, Bonavida B, Miki T . Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biother Radiopharm 2002; 17: 563–567.

    Article  Google Scholar 

  135. 135

    Chopin D, Barei-Moniri R, Maille P, Le Frere-Belda MA, Muscatelli-Groux B, Merendino N et al. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol 2003; 162: 1139–1149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. 136

    Yang H, Li H, Wang Z, Gao J, Guo Y . Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study. Urol Int 2013; 91: 456–461.

    Article  CAS  Google Scholar 

  137. 137

    Gutierrez LS, Eliza M, Niven-Fairchild T, Naftolin F, Mor G . The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat 1999; 54: 245–253.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. 138

    Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000; 89: 127–132.

    Article  CAS  Google Scholar 

  139. 139

    Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D et al. FasL:Fas ratio—a prognostic factor in breast carcinomas. Cancer Res 2000; 60: 822–828.

    CAS  PubMed  PubMed Central  Google Scholar 

  140. 140

    Mullauer L, Mosberger I, Grusch M, Rudas M, Chott A . Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol 2000; 190: 20–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. 141

    Bewick M, Conlon M, Parissenti AM, Lee H, Zhang L, Gluck S et al. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J Hematother Stem Cell Res 2001; 10: 759–768.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. 142

    Munakata S, Watanabe O, Ohashi K, Morino H . Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance. Am J Clin Pathol 2005; 123: 879–885.

    Article  CAS  Google Scholar 

  143. 143

    Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U . Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 2001; 85: 1047–1054.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. 144

    Wu SF, Zhang JW, Qian WY, Yang YB, Liu Y, Dong Y et al. Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis. Eur Rev Med Pharmacol Sci 2012; 16: 2044–2050.

    PubMed  Google Scholar 

  145. 145

    Lerma E, Romero M, Gallardo A, Pons C, Munoz J, Fuentes J et al. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arch 2008; 452: 65–74.

    Article  CAS  Google Scholar 

  146. 146

    Mann B, Gratchev A, Bohm C, Hanski ML, Foss HD, Demel G et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999; 79: 1262–1269.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. 147

    Belluco C, Esposito G, Bertorelle R, Alaggio R, Giacomelli L, Bianchi LC et al. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol 2002; 28: 120–125.

    Article  CAS  Google Scholar 

  148. 148

    Nozoe T, Yasuda M, Honda M, Inutsuka S, Korenaga D . Fas ligand expression is correlated with metastasis in colorectal carcinoma. Oncology 2003; 65: 83–88.

    Article  CAS  Google Scholar 

  149. 149

    Zhang W, Ding EX, Wang Q, Zhu DQ, He J, Li YL et al. Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol 2005; 11: 3632–3635.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. 150

    Li H, Fan X, Stoicov C, Liu JH, Zubair S, Tsai E et al. Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterol 2009; 137: 934–944.

    Article  CAS  Google Scholar 

  151. 151

    Hoogwater FJ, Snoeren N, Nijkamp MW, Gunning AC, van Houdt WJ, de Bruijn MT et al. Circulating CD95-ligand as a potential prognostic marker for recurrence in patients with synchronous colorectal liver metastases. Anticancer Res 2011; 31: 4507–4512.

    PubMed  Google Scholar 

  152. 152

    Kykalos S, Mathaiou S, Karayiannakis AJ, Patsouras D, Lambropoulou M, Simopoulos C . Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases. J Gastrointest Cancer 2012; 43: 224–228.

    Article  CAS  Google Scholar 

  153. 153

    Saigusa S, Tanaka K, Ohi M, Toiyama Y, Yasuda H, Kitajima T et al. Clinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy. Mol Clin Oncol 2015; 3: 151–156.

    Article  PubMed  PubMed Central  Google Scholar 

  154. 154

    Tsutsumi S, Kuwano H, Shimura T, Morinaga N, Mochiki E, Asao T . Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 2000; 89: 2560–2564.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. 155

    Ichikura T, Majima T, Uchida T, Okura E, Ogawa T, Mochizuki H . Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. Oncol Rep 2001; 8: 311–314.

    CAS  PubMed  Google Scholar 

  156. 156

    Nagashima H, Mori M, Sadanaga N, Mashino K, Yoshikawa Y, Sugimachi K . Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int J Oncol 2001; 18: 1157–1162.

    CAS  PubMed  PubMed Central  Google Scholar 

  157. 157

    Osaki M, Kase S, Kodani I, Watanabe M, Adachi H, Ito H . Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis. Gastric Cancer 2001; 4: 198–205.

    Article  CAS  Google Scholar 

  158. 158

    Zheng HC, Sun JM, Wei ZL, Yang XF, Zhang YC, Xin Y . Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroenterol 2003; 9: 1415–1420.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. 159

    Nada O, Abdel-Hamid M, Ismail A, El Shabrawy L, Sidhom KF, El Badawy NM et al. The role of the tumor necrosis factor (TNF)—Fas L and HCV in the development of hepatocellular carcinoma. J Clin Virol 2005; 34: 140–146.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. 160

    Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F et al. Fas ligand in human serum. Nat Med 1996; 2: 317–322.

    Article  CAS  Google Scholar 

  161. 161

    El Bassiouny AE, El-Bassiouni NE, Nosseir MM, Zoheiry MM, El-Ahwany EG, Salah F et al. Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma. Medscape J Med 2008; 10: 130.

    PubMed  PubMed Central  Google Scholar 

  162. 162

    Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003; 63: 5573–5581.

    CAS  Google Scholar 

  163. 163

    Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H et al. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000; 82: 1446–1452.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. 164

    Taylor DD, Lyons KS, Gercel-Taylor C . Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol 2002; 84: 443–448.

    Article  PubMed  PubMed Central  Google Scholar 

  165. 165

    Chaudhry P, Srinivasan R, Patel FD, Gopalan S, Majumdar S . Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer. Int J Cancer 2008; 122: 1716–1721.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. 166

    Bellone G, Smirne C, Carbone A, Mareschi K, Dughera L, Farina EC et al. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. Clin Cancer Res 2000; 6: 2448–2455.

    CAS  PubMed  PubMed Central  Google Scholar 

  167. 167

    Hazar V, Berber Z, Pestereli E, Coskun M, Yesilipek A, Karpuzoglu G et al. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies. Pediatr Hematol Oncol 2005; 22: 247–256.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. 168

    Macher-Goeppinger S, Bermejo JL, Wagener N, Hohenfellner M, Haferkamp A, Schirmacher P et al. Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett 2011; 301: 203–211.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. 169

    Somma P, Lo Muzio L, Mansueto G, Delfino M, Fabbrocini G, Mascolo M et al. Squamous cell carcinoma of the lower lip: FAS/FASL expression, lymphocyte subtypes and outcome. Int J Immunopathol Pharmacol 2005; 18: 59–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. 170

    Sejima T, Morizane S, Hinata N, Yao A, Isoyama T, Saito M et al. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy. Urol Int 2012; 88: 263–270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. 171

    Muraki Y, Tateishi A, Seta C, Fukuda J, Haneji T, Oya R et al. Fas antigen expression and outcome of oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2000; 29: 360–365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. 172

    Fang L, Sun L, Hu FF, Chen QE . Effects of FasL expression in oral squamous cell cancer. Asian Pac J Cancer Prev 2013; 14: 281–285.

    Article  PubMed  PubMed Central  Google Scholar 

  173. 173

    Hara S, Miyake H, Nakamura I, Arakawa S, Kamidono S, Hara I . Increased Fas ligand expression in the tumor tissue and serum of patients with testicular germ cell tumors with seminomatous elements. Urology 2001; 58: 471–476.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. 174

    Baldini E, Ulisse S, Marchioni E, Di Benedetto A, Giovannetti G, Petrangeli E et al. Expression of Fas and Fas ligand in human testicular germ cell tumours. Int J Androl 2009; 32: 123–130.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. 175

    Rzeszutko M, Rzeszutko W, Dziegiel P, Balcerzak W, Kaliszewski K, Bolanowski M . Expression of FAS/APO 1/CD 95 in thyroid tumors. Folia Histochem Cytobiol 2007; 45: 87–91.

    CAS  PubMed  Google Scholar 

  176. 176

    Owonikoko TK, Hossain MS, Bhimani C, Chen Z, Kim S, Ramalingam SS et al. Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer 2013; 119: 1503–1511.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  177. 177

    Lin HC, Lai PY, Lin YP, Huang JY, Yang BC . Fas ligand enhances malignant behavior of tumor cells through interaction with Met, hepatocyte growth factor receptor, in lipid rafts. J Biol Chem 2012; 287: 20664–20673.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  178. 178

    Liu Q, Tan Q, Zheng Y, Chen K, Qian C, Li N et al. Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation. J Biol Chem 2014; 289: 11522–11535.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  179. 179

    Nakamoto Y, Kaneko S, Fan H, Momoi T, Tsutsui H, Nakanishi K et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med 2002; 196: 1105–1111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  180. 180

    Park SM, Rajapaksha TW, Zhang M, Sattar HA, Fichera A, Ashton-Rickardt PG et al. CD95 signaling deficient mice with a wild-type hematopoietic system are prone to hepatic neoplasia. Apoptosis 2008; 13: 41–51.

    Article  CAS  PubMed  Google Scholar 

  181. 181

    Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q et al. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol 2012; 188: 5954–5961.

    Article  CAS  PubMed  Google Scholar 

  182. 182

    Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 2006; 12: 3705–3712.

    Article  CAS  PubMed  Google Scholar 

Download references


SB and WP are supported in part by NIH/NCI training grant T32CA09560. PC is supported by a DOD postdoctoral fellowship W81XWH-13-1-0301. MEP is supported by R01 CA149356.

Author information



Corresponding author

Correspondence to M E Peter.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Edited by G Melino

Rights and permissions

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Peter, M., Hadji, A., Murmann, A. et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ 22, 549–559 (2015).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links